how is cryptocurrency worth anything Top Featured

18 shares were rated by brokers, and Yuhetian's target increased by 54.72%. On December 11th, a total of 18 shares were rated by brokers, and 6 of them announced their target prices. According to the highest target price, Yuhetian, Steady Medical Care and Fulongma ranked in the top, with increases of 54.72%, 19.96% and 17.62% respectively. Judging from the direction of rating adjustment, the ratings of 12 stocks remain unchanged and 6 stocks are rated for the first time. In addition, one stock attracted the attention of many brokers, and Hagrid Communications was ranked in the top number, with two brokers rating it respectively. Judging from the Wind industry to which the rated stocks are bought, the number of rated stocks for technical hardware and equipment, capital goods and materials II is the largest, with 4, 3 and 2 respectively.Institution: The Swiss National Bank does not need to cut interest rates sharply again. Melanie Debono, a macroeconomic analyst at Pantheon, wrote in a report that the Swiss National Bank does not need to cut borrowing costs sharply again. Earlier, the Swiss National Bank unexpectedly cut interest rates by 50 basis points. Most analysts had expected a more cautious rate cut of 25 basis points. Debono said that there may be further relaxation after this move, but only a little. Pantheon Macroeconomics predicts that the Swiss National Bank will cut interest rates by 25 basis points again in March next year.Australia's ASX 200 index narrowed to 0.1%, and the Australian dollar increased. The just released Australian employment data was better than expected.

German Foreign Minister: Ukraine needs hard security.The New Zealand dollar just broke through the 0.5800 mark against the US dollar, and the latest report was 0.5801, up 0.29% in the day; The Australian dollar just broke through the 0.6400 mark against the US dollar, and the latest report was 0.6401, up 0.51% in the day.Laimei Pharmaceutical Co., Ltd.: The controlling shareholder intends to transfer 23.43% of the shares by agreement. Laimei Pharmaceutical announced that Zhongheng Group, the controlling shareholder, intends to transfer 247 million shares of the company's unrestricted tradable A shares by public solicitation of the transferee, accounting for 23.43% of the company's total share capital, and the transfer price is not less than 4.42 yuan/share. If the share transfer is completed, the controlling shareholder and actual controller of the company may change.

Yin Zhongyu, Federal Reserve Securities: Industrial M&A will always have the opportunity to cross-border M&A and will never be supported on a large scale. Yin Zhongyu, assistant to the president of Federal Reserve Securities and head of the M&A business department, pointed out that M&A has ushered in a rare policy window. For industrial M&A, the policy window has always been there. "In particular, industrial M&A focusing on new productivity has always been the direction encouraged by the regulatory authorities, and there will always be opportunities. However, for buying and selling shells and cross-border restructuring, related risks need to be vigilant, and cross- (21 Finance)The New Zealand dollar just broke through the 0.5800 mark against the US dollar, and the latest report was 0.5801, up 0.29% in the day; The Australian dollar just broke through the 0.6400 mark against the US dollar, and the latest report was 0.6401, up 0.51% in the day.Market News: Little Red Book's net profit will exceed $1 billion in 2024.